A replay of the call can be accessed by dialing (888) 286-8010 (domestic)
or (617) 801-6888 (international) and the passcode is 33917395.

ind agus

CancerVax Corporation (NASDAQ: CNVX), a
biotechnology company focused on the research, development and
commercialization of novel biological products for the treatment of cancer,
will host a conference call and live webcast on Wednesday, March 15, 2006
at 9:00am. Doubletree Ranch Rd.

p baile

Food and Drug Administration will not
approve CancerVax' IND for D93, or that such approval will be delayed or
require substantial additional testing and information , which could result
in increased costs and uncertainty; CancerVax's ability to initiate the
planned Phase 1 clinical trial for D93 and otherwise successfully develop
this and CancerVax's other product candidates, which are in early stages of
development and are subject to a high risk of failure; the Company's
dependence on sole-source suppliers to provide its product candidates,
including D93 , for early-stage clinical trials; CancerVax's ability to
successfully manage its remaining resources , including available cash,
while it seeks to implement the merger with Micromet; the risk that, in the
event that the merger with Micromet is not successful, CancerVax may be
unable to access additional capital necessary to continue to fund its
operations and new product development programs; and other risks detailed
in CancerVax's Securities and Exchange Commission filings, including
CancerVax 's registration statement on Form S-4 filed with the SEC on
February 13, 2006, CancerVax's Annual Report on Form 10-K for the fiscal
year ended December 31, 2004, and Quarterly Report for the fiscal quarter
ended September 30, 2005.

gn ind

cancervax.m.

Contacts:
Amendola Communications - 480-664-8412
Jan Shulman, jshulman@acmarketingpr.

eala siopad

cancervax.

world eoraip

thchleas teangacha

com)

CancerVax Corporation is a biotechnology company focused on the research,
development and commercialization of novel biological products for the
treatment and control of cancer.RealEstateMarketingExpo.com or by calling 800-230 -1034.

ag eola

Any forward-looking statements are made pursuant to Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and, as such, speak only as of the date
made.m.-9:00 a.

ind siopad

-12:30p.

WHO: REALTOR.com
Jodi Amendola, jamendola@acmarketingpr.

eoraip agus

About CancerVax Corporation (www., and
application will be made to NASDAQ to change the ticker symbol to
"MITI. Securities and Exchange Commission in connection
with the transaction.

Forward-Looking Statements

CancerVax cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements. Investors and securityholders
of CancerVax and Micromet are urged to read the proxy statement/prospectus
(including any amendments or supplements to the proxy statement /prospectus)
regarding the proposed transaction because it contains important
information about CancerVax, Micromet and the proposed transaction.

eorpach baile

The conference call will be webcast simultaneously over the Internet.
For example, statements about the Company's expectations, beliefs, plans,
objectives , assumptions or future events or performance are not historical
facts and are all forward-looking statements. CancerVax undertakes no obligation to publicly update any
forward-looking statements , whether as a result of new information, future
events or otherwise.

eoraip teangeola

Pacific) to discuss financial results for the
fourth quarter and full year ended December 31, 2005.m.-12:30 p.

eala nach

PRESS RELEASE CancerVax Corporation to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Full Year 2005 Financial Results

Alternatively, callers may participate
in the conference call by dialing (866) 270-6057 (domestic) or (617)
213-8891 (international). Additional
information regarding the directors and executive officers of CancerVax is
also included in CancerVax's proxy statement for its 2005 Annual Meeting of
Stockholders, which was filed with the SEC on April 28, 2005.

gaeilge ire

Eastern (6:00am. CancerVax filed an
investigational new drug application and plans to initiate a Phase 1
clinical trial with D93 in patients with solid tumors in 2006.

eola teangeola

CancerVax will be renamed "Micromet," Inc. Wednesday, April 27th, 9:00a.m.

pobal eala

sec.

eoraip thchleas

In January 2006, CancerVax announced that it had entered into a definitive
agreement to merge with Micromet, AG, a private, Munich, Germany-based
biotechnology company with a focus on the development of novel, proprietary
antibody-based products for cancer and inflammatory and autoimmune
diseases. The merger, which is subject to a number of conditions , is
expected to close in the second quarter of 2006.

Participants in the Solicitation

CancerVax and its directors and executive officers and Micromet and its
directors and executive officers may be deemed to be participants in the
solicitation of proxies from the stockholders of CancerVax in connection
with the proposed transaction.

ist ir

S. Copies of the proxy statement/prospectus and the
filings with the SEC that are incorporated by reference in the proxy
statement/prospectus can also be obtained, without charge, by directing a
request to CancerVax Corporation, 2110 Rutherford Road, Carlsbad, CA 92008,
Attention: Investor Relations, Telephone: (760) 494-4200.com

nach agus

President and CEO David F.
In addition, he will discuss the Company's recently announced signing of a
definitive merger agreement with Micromet AG, one of the leading privately
held European biopharmaceutical companies focused on the development of
antibody-based drugs. The webcast will be
archived on this site for one year. Upon closing of the
transaction, the Company's shares are expected to continue to trade on the
NASDAQ National Market.m.

gaeilge nach

To
listen, please visit the Investor Relations section of CancerVax's
corporate web site at http://ir." On February 13, 2006, CancerVax filed a registration statement on
Form S-4 with the U.
CancerVax's stockholders can obtain a free copy of the proxy
statement/prospectus, as well as other filings containing information about
CancerVax and Micromet, without charge, at the SEC's Internet site
(http://www.gov). Information regarding the special interests
of these directors and executive officers in the merger transaction are
included in the proxy statement/prospectus referred to above. This document
is available free of charge at the SEC's web site (http://www.com(R) and TOP PRODUCER(R)

WHAT: Valley agents, brokers and office managers are invited to this
free

Real Estate Marketing EXPO to learn how to:
* Secure more listings in the "hot" Phoenix marketplace;
* Incorporate best practices of top producing agents;
* Grow your business;
* Leverage the power of the Internet;
* Build customer loyalty and word-of-mouth referrals and
* Much more!

WHEN: Wednesday , April 27th, 9:00 a.

agus nuacht

S.
Scottsdale, AZ 85258

HOW: Seating is limited ! Pre-register online at
http://www.

world thchleas

This registration statement contains a proxy
statement /prospectus. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof.

Additional Information about the Merger and Where to Find It

In connection with the proposed merger transaction with Micromet, AG, on
February 13, 2006 , CancerVax filed with the SEC a registration statement
that contains a proxy statement/prospectus .

WHERE: Hyatt Regency Scottsdale at Gainey Ranch
7500 E.

teangacha teangeola

The Company 's actual results and the
timing of events may differ materially from those set forth in this release
as a result of certain risks and uncertainties, including, without
limitation: the risk that the U.gov) and
from Investor Relations at CancerVax at the address described above.

nach teangacha

Hale will provide an update of the Company's
pipeline of biological products for the treatment and control of cancer .com. The passcode for the conference call is 84899170. The Company's leading product candidate is
D93 , an anti-angiogenic, humanized, monoclonal antibody.

Valley Realtors(R) Invited to Free Real Estate Marketing Expo Featuring 'The Don'ts + Dos of Real Estate Marketing'

ire ocht

These forward-looking
statements, which may be identified by the use of words or phrases such as
"believe," "may," "could," "will, " "estimate," "continue," "anticipate,"
"intend," "seek," "plan," "expect," "should," or "would," are based upon
CancerVax's current expectations.sec.
Continental breakfast served from 8:30 a.m.